Minocycline topical gel - Foamix

Drug Profile

Minocycline topical gel - Foamix

Latest Information Update: 06 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Foamix
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Age-related macular degeneration; Blepharitis; Chlamydial infections; Diabetic macular oedema; Glaucoma; Ophthalmic infections; Rosacea

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Jun 2014 Foamix enters into a collaboration with the National Eye Institute to develop therapeutics for the treatment of geographic atrophy, a form of age-related macular degeneration
  • 28 Aug 2013 Minocycline topical gel - Foamix is available for licensing as of 28 Aug 2013. http://www.foamix.co.il/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top